Clinical Trials Logo

Cervical Lesion clinical trials

View clinical trials related to Cervical Lesion.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT06463938 Recruiting - Dentin Sensitivity Clinical Trials

A Clinical Trial to Compare Lasotronix Alone or in Combination With CPP-ACP to Treat DH

Start date: May 12, 2024
Phase: N/A
Study type: Interventional

Dentin hypersensitivity (DH) is defined as sharp pain of a shorter duration arise from exposed dentin in response to several chemicals and thermal or tactile stimuli that cannot be ascribed to other dental defects". DH has a prevalence rate ranging from 1.3% to 92.1%, commonly affecting old ages. The use of laser has opened new dimensions in the treatment of DH. To the author's knowledge, not much research work has been conducted using LASOTRONIX as a treatment modality with CPP-ACP. Therefore, this research aims to determine the effectiveness of Casein phospho peptide paste (CPP-ACP) used alone or combined with a diode laser (LASOTRONIX).

NCT ID: NCT06276309 Recruiting - Cervical Cancer Clinical Trials

Protein Molecular Characteristics and Prognosis of Cervical Neuroendocrine Tumors

Start date: February 1, 2024
Phase:
Study type: Observational

The clinical diagnosis and treatment data of 300 cases of cervical neuroendocrine tumors were collected, including age, preoperative biopsy pathology results, postoperative histopathological results, TCT results, and colposcopy biopsy pathology results. At the same time, paraffin tissue specimens (remaining specimens after pathological diagnosis) from 100 cases of cervical neuroendocrine tumors from multiple centers across the country were collected to establish a cervical neuroendocrine tumor data follow-up database. Protein concentration and omics analysis were performed on the data results, to evaluate the molecular characteristics and prognosis of cervical neuroendocrine tumor proteins, and to preliminarily explore its clinical application value.

NCT ID: NCT05870787 Recruiting - Cervical Cancer Clinical Trials

iMproving thE DIagnostics And Treatment Of ceRvical Precancer

MEDIATOR
Start date: March 1, 2023
Phase:
Study type: Observational [Patient Registry]

Cervical cancer screening is important as it enables identification of women at increased risk of the disease, but high-quality diagnostics of screen-positive women and effective treatment of those with precancer are critical in preventing progression to cancer. With the current transition from cytology-based to primary human papillomavirus (HPV)-screening and a growing proportion of HPV-vaccinated women, diagnostics of screen-positive women will become more challenging in the decades to come. Thus, there is a need to explore how to improve diagnostics while ensuring a low number of unnecessary procedures such as colposcopy and the collection of multiple cervical biopsies. The overall purpose is: - To investigate the diagnostic accuracy of cervical precancer when using a colposcopic scoring system in the diagnostic work-up of screen-positive women. - To investigate the performance of a colposcopic scoring system to identify women without cervical precancer in whom collection of biopsies can be safely omitted.

NCT ID: NCT05851079 Recruiting - Clinical trials for Cervical Intraepithelial Neoplasia Grade 2/3

Accurate Screening and Prevention of Cervical Lesions-- Development of Accurate Screening Methods for Cervical Lesions

Start date: December 10, 2021
Phase:
Study type: Observational [Patient Registry]

The goal of this observational study is to compare the accuracy and sensitivity of High-throughput human papilloma virus(HPV) typing and integrated assays with routine screening protocols (Cobas HPV test combined with thinprep cytologic test(TCT) for the detection of cervical intraepithelial neoplasia in the general and hospital populations. The main questions it aims to answer are: - High-throughput HPV typing and integrated assays can screen for ≥ cervical intraepithelial neoplasia (CIN2 or CIN3) with high sensitivity and accuracy. - High-throughput HPV typing and integrated assays can be promoted as a screening tool for cervical cancer. Participants will be screened with routine screening protocols (Cobas HPV test combined with TCT test), and if the results are abnormal, colposcopy and cervical biopsy will be performed.

NCT ID: NCT04249856 Recruiting - Cervical Cancer Clinical Trials

Colposcopy and Dynamic Spectral Imaging (DSI)

Start date: February 1, 2017
Phase:
Study type: Observational

This study evaluates the Dynamic Spectral Imaging (DSI) Colposcope (DySIS) in it's ability to diagnose cervical dysplasia. Half of participants with be examined by the DySIS colposcope, there the other half will be examined by standard colposcopy.